New Dosing Recommendations Retrovir (Zidovudine) Syrup for HIV-Infected Infants
November 6, 2009
On November 6, 2009, the Food and Drug Administration (FDA) approved revised pediatric dosing recommendations that expand dosing to include children starting treatment at four weeks of age.
The revised label contains the following recommendation:
The recommended dosage in pediatric patients 4 weeks of age and older and weighing >4 kg is provided in Table 1. RETROVIR Syrup should be used to provide accurate dosage when whole tablets or capsules are not appropriate.
Table 1: Recommended Pediatric Dosage of RETROVIR
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)